We are BrainsWay

What BrainsWay is all about

BrainsWay is dedicated to developing and providing advanced solutions for brain disorders using its revolutionary technology, Deep Transcranial Magnetic Stimulation (Deep TMS). The company was established in 2003, became a public company traded on the Tel-Aviv Stock Exchange in January 2007 and NASDAQ (BWAY) in April 2019. BrainsWay’s treatment is based on patents filed jointly by the company and the U.S. National Institutes of Health (NIH), and held exclusively by BrainsWay.

BrainsWay is FDA-cleared for treating adult patients suffering from Major Depressive Disorder (MDD) who failed to achieve satisfactory improvement from previous anti-depressant medication treatment in the current episode (FDA 510(k) No. K122288). BrainsWay is also approved in Canada for the treatment of Major Depressive Disorder (Health Canada Licence No. 90504).

BrainsWay is also FDA-cleared as an intended adjunct treatment for adult patients suffering from Obsessive-Compulsive Disorder (OCD) (FDA De Novo No. DEN170078).

Furthermore, BrainsWay holds CE Mark clearance outside of North America for numerous additional psychiatric and neurological conditions, including Post-Traumatic Stress Disorder (PTSD) and Alzheimer’s Disease (AD).

BrainsWay collaborates with leading scientists and academic research institutions worldwide in clinical trials covering various neuropsychiatric and neuroscience applications.

The company’s technology has already helped thousands of patients worldwide regain well-being in private clinics, hospitals, and clinical studies.

Our Leadership Team

Christopher von Jako

Christopher R von Jako, PhD

President and Chief Executive Officer (CEO)

Judy Huber

Senior VP and Chief Financial Officer (CFO)

Hadar Levy - Chief Financial Officer at BrainsWay

Hadar Levy

Senior VP and GM of North America

Moria Ankry

VP of Research & Development

Chris Boyer

Christopher Boyer

VP of Global Marketing

Amit Ginou - VP of Field & Clinical Operations at BrainsWay

Amit Ginou

VP and Site Manager

Yiftach Roth, PhD - Founder of BrainsWay

Yiftach Roth, PhD

Chief Scientific Officer (CSO)

Aron Tendler MD

Aron Tendler, MD, C.BSM

Chief Medical Officer (CMO)

David Zacut - Director at BrainsWay

David Zacut, MD

Chairman of the Board

Yossi Ben Shalom

Yossi Ben Shalom

Board Director

Avner Hagai - Director at BrainsWay

Avner Hagai

Board Director

Avner Lushi

Avner Lushi

Board Director

Gavriel Magen - Director at BrainsWay

Gavriel Magen

Board Director

Eti Mitrany - Director at BrainsWay

Eti Mitrany

Board Director

Karen Sarid - Director at BrainsWay

Karen Sarid

Board Director

Orly Uri - Director at BrainsWay

Orly Uri

Board Director

Avraham Zangen, PhD - Sits on the Scientific Advisory Board at BrainsWay

Avraham Zangen, PhD

Board Director

Avner Hagai - Director at BrainsWay

Avner Hagai

Board Director

Yiftach Roth, PhD - Founder of BrainsWay

Yiftach Roth, PhD

Chief Scientific Officer (CSO)

David Zacut - Director at BrainsWay

David Zacut, MD

Chairman of the Board

Avraham Zangen, PhD - Sits on the Scientific Advisory Board at BrainsWay

Avraham Zangen, PhD

Board Director

Join Us

A career with BrainsWay is more than just a job. It’s personal. As a leader in non-invasive brain stimulation we’re deeply committed to help patients who suffer from brain disorders. If you’re a natural problem-solver with the imagination, courage and spirit to make a meaningful difference, BrainsWay is where you want to build your career.

Current Open Positions

News & Events

See all the latest news, events and in the media BrainsWay has to offer, and everything in-between.

7 July, 2020

Dr. Pamela Kurth of Achieve TMS East Highlights Deep TMS in Glastonbury Life

Dr. Pamela Kurth of Achieve TMS East describes the challenges of treating depression with traditional...

24 June, 2020

BrainsWay Reports First Quarter 2020 Financial Results and Operational Highlights

PATTERSON, N.J. and JERUSALEM, Israel, June 24, 2020 (GLOBE NEWSWIRE) – BrainsWay Ltd. (NASDAQ...

17 June, 2020

BrainsWay Chief Medical Officer Evaluates the Merits of Telepsychiatry in Psychiatric Times

Dr. Aron Tendler, BrainsWay’s chief medical officer, weighs the pros and cons of telepsychiatry...